STSimon Turcotte

Simon Turcotte

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Simon Turcotte has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multi-Institutional CT Scan-Based Radiomics for Predicting Tumor PD-L1 Expression in Patients with Advanced and Limited Non-Small Cell Lung Cancer

    by Ralph Saber, Marion Tonneau, Olivier Salko, Moishe Liberman, Julie Malo, Arielle Elkrief, Simon Turcotte, Nicole Bouchard, Philippe Joubert, Samuel Kadoury, et al.

    Background/Objectives: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape of advanced non-small cell lung cancer (NSCLC), yet 70% of patients experience disease progression, underscoring the critical need for predictive biomarkers. Programmed death-ligand 1 (PD-L1) expression remains the most adopted biomarker for ICIs. With the emergence of machine learning, the development of radiomics algorithms based on CT scan images has demonstrated potential as a novel addition to the biomarker landscape in oncology. In this study, we aimed to develop a non-invasive surrogate of PD-L1 expression (rad-PDL1) derived from computed tomography (CT) scan imaging and compare its predictive value to pathological assessments. Furthermore, we evaluated its generalizability across advanced and limited-stage NSCLC. Methods: Radiomics features extracted from pretreatment CT were analyzed using a self-training pipeline that incorporated the feature tokenizer Transformer model to classify tumors as high vs. low PD-L1 expression. We included 482 advanced NSCLC patients treated with ICIs across three medical centers who were divided into training and hold-out validation sets. The algorithm was then further validated in an independent cohort of 51 patients with limited NSCLC treated with neoadjuvant ICI and chemotherapy. Results: Our pipeline demonstrated strong predictive performance in primary and independent validation (AUC = 0.75 and 0.68, accuracy = 0.73 and 0.69, respectively), highlighting its generalizability and adaptability to various disease stages. Kaplan–Meier curves revealed a longer progression-free survival for patients in the high rad-PDL1. Conclusions: These results demonstrate the feasibility of a CT-based radiomic surrogate of PD-L1 expression, showing partial generalization to an independent neoadjuvant cohort, while highlighting the need for larger prospective multi-site validation before clinical implementation.


  • Open Access

    Gender differences in the plasma profiles of PCSK9, soluble LDLR, total cholesterol, and triglycerides in patients with colorectal cancer liver metastases: diagnostic and prognostic implications

    by Clara Lafortune, Yara Haddad, Mieczyslaw Marcinkiewicz, Michel Chrétien, Simon Turcotte, Majambu Mbikay

    Background. Proprotein convertase subtilisin/kexin-type 9 (PCSK9) and soluble low-density lipoprotein receptor (sLDLR) are blood proteins that down regulate LDLR-mediated uptake of plasma LDL-cholesterol into cells. In healthy subjects, the plasma level of PCSK9 and sLDLR strongly correlates with that of total cholesterol (TC) and triglycerides (TG), respectively. Since cancer is known to reprogram lipid metabolism, it may also alter the plasma levels of PCSK9 and sLDLR as well as their correlations with TC and TG. To verify this hypothesis, we measured the levels of PCSK9, sLDLR, TC, and TG in the plasma of healthy subjects and patients with colorectal cancer liver metastases (CRLM), categorized as early recurrent (ER) or non-recurrent (NR) after liver resection. Methods. The plasma levels of PCSK9 and sLDLR were determined using specific ELISA kits, those of TC and TG by enzymatic colorimetry. Results. Relative to healthy subjects, CRLM patients carried 4 to 6 higher levels of sLDLR, irrespective of category or gender ( p < 0.0001). These levels strongly correlated with those of TG ( p < 0.0001). PCSK9 correlations with sLDLR, TC, or TG varied with gender or CRLM category. Low PCSK9 levels were associated with large tumor size in CRLM_ER, particularly in women ( p < 0.01). Also in women, a TC level above the median is predictive of a poor 5-year overall survival [HR (95% CI) 1.70 (1.07 – 2.71; p = 0.0152]. Conclusions. High plasma sLDLR is a potential diagnostic biomarker of CRLM. In CRLM_ER women, low plasma PCSK9 indicates the presence of large tumors and, in CRLM women in general, high plasma TC is an unfavorable prognostic biomarker. Thus, early recurrence and gender ought to be considered when examining the clinical significance of lipid dysregulation in CRLM patients.

  • Open Access

    Glutaminase Reprogramming in Hepatocellular Carcinoma: Implications for Diagnosis, Prognosis, and Potential as a Novel Therapeutic Target

    by Vincent Tambay, Valérie-Ann Raymond, Simon Turcotte, Marc Bilodeau

    Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer, with a poor prognosis due to late diagnosis, limited curative therapies, and underlying liver disease. Glutamine metabolism, a crucial pathway in cancer, remains poorly understood in HCC, which develops in an already metabolically dynamic organ. This study aimed to characterize glutamine metabolism in HCC. Glutamine metabolism in HCC was explored through in vitro analysis of neoplastic characteristics, experimental hepatocarcinogenesis in C57BL/6 mice, and examination of liver samples from patients with HCC, cirrhosis, and non-diseased liver. The evaluation included metabolite abundance and mRNA/protein expressions. In mice, tumors exhibited hyperactive glutaminolysis compared to adjacent tissue. Notably, glutaminase expression shifted from the liver isoform (GLS2) in normal and cirrhotic livers to the kidney isoform (GLS1) in HCC. In samples from patients, HCC tumors showed overexpression of glutamine synthetase and GLS1 along with a loss of GLS2 expression, providing excellent discrimination of HCC lesions from cirrhotic and normal liver samples. Inhibiting GLS1 with CB-839 significantly impacted glutamine metabolism in HCC cells while showing limited activity on normal hepatocytes. HCC tumors show reprogramming of GLS2 to GLS1, with a concomitant increase in glutamine synthetase. These characteristics can discriminate HCC from cirrhotic and normal liver tissues. Overexpressed GLS1 and loss of GLS2 within tumors convey an unfavorable prognosis in patients with HCC. Pharmacological inhibition of GLS1 in HCC cells successfully harnesses glutamine metabolism, representing an attractive target for novel therapeutic approaches.


  • Open Access

    Implementing Person-Centered, Clinical, and Research Navigation in Rare Cancers: The Canadian Cholangiocarcinoma Collaborative (C3)

    by Samar Attieh, Leonard Angka, Christine Lafontaine, Cynthia Mitchell, Julie Carignan, Carolina Ilkow, Simon Turcotte, Rachel Goodwin, Rebecca C. Auer, Carmen G. Loiselle

    Person-centered navigation (PCN) in healthcare refers to a proactive collaboration among professionals, researchers, patients, and their families to guide individuals toward timely access to screening, treatment, follow-up, and psychosocial support. PCN—which includes professional, peer, and virtual guidance, is particularly crucial for rare cancers, where affected individuals face uncertainty, limited support, financial strain, and difficulties accessing relevant information, testing, and other services. The Canadian Cholangiocarcinoma Collaborative (C3) prioritizes PCN implementation to address these challenges in the context of Biliary Tract Cancers (BTCs). C3 uses a virtual PCN model and staffs a “C3 Research Navigator” who provides clinical and research navigation such as personalized guidance and support, facilitating access to molecular testing, clinical trials, and case reviews through national multidisciplinary rounds. C3 also supports a national network of BTC experts, a patient research registry, and advocacy activities. C3’s implementation strategies include co-design, timely delivery of support, and optimal outcomes across its many initiatives. Future priorities include expanding the C3 network, enhancing user engagement, and further integrating its innovative approach into routine care.


  • Open Access

    Metabolomics-Guided Identification of a Distinctive Hepatocellular Carcinoma Signature

    by Vincent Tambay, Valérie-Ann Raymond, Corentine Goossens, Louise Rousseau, Simon Turcotte, Marc Bilodeau

    Background: Hepatocellular carcinoma (HCC) is a major contributor to cancer-related morbidity and mortality burdens globally. Given the fundamental metabolic activity of hepatocytes within the liver, hepatocarcinogenesis is bound to be characterized by alterations in metabolite profiles as a manifestation of metabolic reprogramming. Methods: HCC and adjacent non-tumoral liver specimens were obtained from patients after HCC resection. Global patterns in tissue metabolites were identified using non-targeted 1H Nuclear Magnetic Resonance (1H-NMR) spectroscopy whereas specific metabolites were quantified using targeted liquid chromatography–mass spectrometry (LC/MS). Results: Principal component analysis (PCA) within our 1H-NMR dataset identified a principal component (PC) one of 53.3%, along which the two sample groups were distinctively clustered. Univariate analysis of tissue specimens identified more than 150 metabolites significantly altered in HCC compared to non-tumoral liver. For LC/MS, PCA identified a PC1 of 45.2%, along which samples from HCC tissues and non-tumoral tissues were clearly separated. Supervised analysis (PLS–DA) identified decreases in tissue glutathione, succinate, glycerol-3-phosphate, alanine, malate, and AMP as the most important contributors to the metabolomic signature of HCC by LC/MS. Conclusions: Together, 1H-NMR and LC/MS metabolomics have the capacity to distinguish HCC from non-tumoral liver. The characterization of such distinct profiles of metabolite abundances underscores the major metabolic alterations that result from hepatocarcinogenesis.


  • Open Access

    Outcomes of Older Patients with Resectable Colorectal Liver Metastases Cancer (CRLM): Single Center Experience

    by Rami Nassabein, Laura Mansour, Corentin Richard, Franck Vandenbroucke-Menu, Francine Aubin, Jean-Pierre Ayoub, Michel Dagenais, Real Lapointe, Richard Letourneau, Marylène Plasse, et al.

    Surgery is the only potential curative option of CRLM if resectable. The curative approach in patients over 70 years old is challenging mainly because of comorbidities and other geriatric syndromes. Herein, we report outcomes of older patients with resectable CRLM in our center. We retrospectively analyzed characteristics and outcomes of older patients with CRLM operated at “Centre Hospitalier de l’Université de Montréal” (CHUM) between 2010 and 2019. We identified 210 patients aged ≥70 years with a median age of 76 (range: 70–85). CRLM were synchronous in 56% of patients. Median disease-free survival (DFS) was 41.3 months. Median overall survival (OS) was 62.2 months and estimated 5-year survival rate was 51.5% similar to those of younger counterparts. Patients with metachronous CRLM had a trend to a higher OS compared to those with synchronous disease (67.2 vs. 58.7 months; p = 0.42). Factors associated with lower survival in the multivariate analysis were right-sided tumors and increased Charlson Comorbidity index (CCI). Survival outcomes of patients aged ≥70 years were comparable to those of younger patients and those reported in the literature. Age should not be a limiting factor in the curative management of older patients with resectable CRLM.